Compounded, not FDA-approved
The peptide named for delta sleep is the thing its own trials kept failing to find
DSIP stands for delta sleep-inducing peptide, a name assigned in 1977 for what the molecule did to rabbit EEGs. In people, the record reads differently: the only parallel-group placebo-controlled insomnia trial ever run, 16 patients in 1992, concluded it is not likely to be of major therapeutic benefit, and the most recent human study, in 2009, found it paradoxically reduced the delta rhythm it is named for. The peptide's own gene, precursor and receptor have never been found. In July 2026 FDA proposed keeping it out of compounding pharmacies, and trade press reports the advisory committee agreed, making it the only one of seven peptides reviewed that was voted down. Every study in our table is labeled by species, every claim carries its grade, and the absences are printed at the same weight as the findings.
- 419papers indexed on this peptide, with a median publication year of 1992 and only 7 since 2016
- 5randomized-tagged studies in that entire literature, enrolling 72 people between them
- 16patients in the largest placebo-controlled insomnia trial, which concluded DSIP is not likely to be of major therapeutic benefit
- 28rows in our evidence table, each labeled by species, including 5 documented absences of evidence
- 42fetch-verified citations, 97.6 percent peer-reviewed or government sources; the single press citation is the attributed committee-vote report
Online care, from intake to delivery
DSIP care, made simple
Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Your care plan includes
Everything you need to get started
Encrypted checkout • provider review required • shipping included
- 01Choose your planSelect the supply and refill preference that works for you.
- 02Complete your intakeShare your health history in our private, secure flow.
- 03Provider reviewIf appropriate, your prescription is prepared and shipped.
Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.
Key facts
- StatusCompounded, not FDA-approved
- Human half-lifeNot established
- Human bioavailability (any route)Not established
- Human Cmax or AUCNot established
- Published human PK studies0
- Half-life, dog, IV4.0 +/- 0.7 minutes
- Metabolic clearance rate, dog, IV30.7 +/- 2.5 mL/kg per minute
- Stability in blood (in vitro)Rapid degradation; analogs aggregate
- Water solubility (free base)About 0.5 mg/mL; sold 1 mg/mL labels questioned by FDA
- ClassSynthetic nonapeptide; sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Molecular weight848.8 Da (C35H48N10O15)
- CAS / UNII62568-57-4 / YN28Z5YZ73
- INNEmideltide (used by exactly one indexed paper, ever)
- MeSH descriptorD003701
- Discovered1977, isolated from cerebral venous blood of sleep-stimulated rabbits
- US FDA statusNot approved for any use; on FDA's compounding safety-risks list
- July 2026 PCACFDA proposed emideltide NOT be added to the 503A Bulks List
- Committee vote (press-reported)Rejected 6-7 with one abstention, per Regulatory Focus; the only one of seven peptides voted down
- Uses FDA evaluatedOpioid withdrawal, chronic insomnia, narcolepsy
- Route in every clinical studyIntravenous infusion, 25 to 150 nmol/kg
- Total documented IV exposure209 subjects, 1 to 15 days (FDA count)
- Data for the sold SC/nasal routesNone identified by FDA
- Indexed literature419 records; median year 1992; 7 since 2016
- RCT-tagged records5, enrolling 72 people in total
- Registered clinical trials today0
- Gene, precursor protein, receptorNever identified
Browse by topic
Everything on DSIP (delta sleep-inducing peptide), organized the way you research it.
Free DSIP (emideltide) tools
Practical calculators and references, each scoped and sourced.
Review-gated tools: these tools are excluded from search and AI citation and must not be used as dosing, reconstitution, injection, or treatment instruction.
All guides
48 in-depth, individually cited guides.
Review-gated archive: the guides below are preserved for individual medical and source review. They are excluded from search indexing and AI citation files.
Evidence 22 guides
Sourcing 8 guides
Safety 7 guides
Dosing 7 guides
Comparisons 4 guides
Email me when the FDA rulemaking lands
The July 2026 proposal is not a final decision. One email when it becomes one. Nothing else.
